Evidence map›Paper›PMID 36165200›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2022

Cross-Talk between HLA Class I and TLR4 Mediates P-Selectin Surface Expression and Monocyte Capture to Human Endothelial Cells.

Yi-Ping Jin, Jessica Nevarez-Mejia, Allyson Q Terry, Rebecca A Sosa, Sebastiaan Heidt, Nicole M Valenzuela, Enrique Rozengurt, Elaine F Reed

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Spatial multiomics of arterial regions from cardiac allograft vasculopathy rejected grafts reveal novel insights into the pathogenesis of chronic antibody-mediated rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024
    Article
  3. Article
  4. Review
  5. The Transplant Bellwether: Endothelial Cells in Antibody-Mediated Rejection.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. PosttransplantFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yi-Ping JinDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0001-6620-4274
Jessica Nevarez-MejiaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-3390-4818
Allyson Q TerryDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-4156-991X
Rebecca A SosaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-9860-6830
Sebastiaan HeidtDepartment of Immunology, Leiden University Medical Center, Leiden, the Netherlands; and.ORCID 0000-0002-6700-188X
Nicole M ValenzuelaDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0003-2024-5382
Enrique RozengurtDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.ORCID 0000-0002-7838-9170
Elaine F ReedDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; ereed@mednet.ucla.edu.ORCID 0000-0002-3524-545X
University of California, Los Angeles · USLeiden University Medical Center · NL

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Regulation of Innate Immune Responses by Alloimmunity in Liver Ischemia-Reperfusion InjuryP01AI120944 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Jerzy W Kupiec-Weglinski · 2017 to 2026
$20.0M
Project 3: Mapping the Evolution of Chronic Transplant Injury in the Context of CMV InfectionU19AI128913 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELASHOFF, DAVID · 2017 to 2021
$11.2M
Vascular Biology Training GrantT32HL069766 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2002 to 2022
$7.4M
Project 3: Role of the pancreatic fibroinflammatory microenvironment in obesity-promoted pancreatic cancerP01CA236585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EIBL, GUIDO ERWIN MICHAEL · 2020 to 2024
$5.6M
The role of HLA and its coreceptors in endothelial cell activation and leukocyte recruitment in antibody-mediated transplant rejectionR01AI135201 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert L Fairchild, ELAINE F REED · 2018 to 2026
$5.3M
Targeting YAP with statins to prevent antibody-mediated transplant rejectionR21AI156592 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, ELAINE F, ROZENGURT, JUAN ENRIQUE · 2021 to 2022
$444k
Identification of the growth-promoting PKD/YAP axis as a novel target for the statins in intestinal epithelial cells.I01BX003801 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI ROZENGURT, JUAN ENRIQUE · 2018 to 2021
–
BLRD VA I01 BX003801NCI NIH HHS P01 CA236585NHLBI NIH HHS T32 HL069766NIAID NIH HHS 75N93019C00052NIAID NIH HHS P01 AI120944NIAID NIH HHS R01 AI135201NIAID NIH HHS R21 AI156592NIAID NIH HHS U19 AI128913
6 · The paper itself

Abstract

Donor-specific HLA Abs contribute to Ab-mediated rejection (AMR) by binding to HLA molecules on endothelial cells (ECs) and triggering intracellular signaling, leading to EC activation and leukocyte recruitment. The molecular mechanisms involving donor-specific HLA Ab-mediated EC activation and leukocyte recruitment remain incompletely understood. In this study, we determined whether TLRs act as coreceptors for HLA class I (HLA I) in ECs. We found that human aortic ECs express TLR3, TLR4, TLR6, and TLR10, but only TLR4 was detected on the EC surface. Consequently, we performed coimmunoprecipitation experiments to examine complex formation between HLA I and TLR4. Stimulation of human ECs with HLA Ab increased the amount of complex formation between HLA I and TLR4. Reciprocal coimmunoprecipitation with a TLR4 Ab confirmed that the crosslinking of HLA I increased complex formation between TLR4 and HLA I. Knockdown of TLR4 or MyD88 with small interfering RNAs inhibited HLA I Ab-stimulated P-selectin expression, von Willebrand factor release, and monocyte recruitment on ECs. Our results show that TLR4 is a novel coreceptor for HLA I to stimulate monocyte recruitment on activated ECs. Taken together with our previous published results, we propose that HLA I molecules form two separate signaling complexes at the EC surface, that is, with TLR4 to upregulate P-selectin surface expression and capture of monocytes to human ECs and integrin β

Indexed as

Endothelial CellsIntercellular Adhesion Molecule-1Cells, CulturedEndothelium, VascularHLA AntigensHumansIntegrin beta4MonocytesMyeloid Differentiation Factor 88P-SelectinToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 6TOR Serine-Threonine Kinasesvon Willebrand FactorHLA AntigensIntegrin beta4Intercellular Adhesion Molecule-1Myeloid Differentiation Factor 88P-SelectinTLR4 protein, humanToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 6TOR Serine-Threonine Kinasesvon Willebrand Factor

Identifiers

PMID36165200
PMCPMC9635437
OpenAlexW4297261087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.